GVOKE HYPOPEN
Peakglucagon injection, solution
NDASUBCUTANEOUSSOLUTION
Approved
Sep 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
GVOKE HYPOPEN (glucagon injection, solution) is 12. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GVOKE HYPOPEN is a ready-to-use glucagon injection solution designed to rapidly treat severe hypoglycemia in patients with type 1 diabetes mellitus. It works by activating hepatic glucagon receptors to stimulate glycogen breakdown and glucose release from the liver, increasing blood glucose by an average of 176 mg/dL in adults within approximately 50 minutes of subcutaneous injection.
Peak9.8 years to LOE
GVOKE is in peak commercial phase with strong market positioning; teams are focused on maintaining market share and expanding into new patient segments rather than high-growth expansion.
Mechanism of Action
12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.